Pancreatic Cancer Research

ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Liangliang Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5611-2704; OpenAlex author ID A5101970902, A5101970904. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
37
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps. Co-author DOI 10.1158/0008-5472.can-26-0151↗
  2. CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway. Co-author DOI 10.20892/j.issn.2095-3941.2025.0058↗
  3. Revealing splenectomy-driven microRNA hsa-7b-5p's role in pancreatic cancer progression. Co-author DOI 10.1016/j.isci.2024.109045↗
  4. Retraction notice to "HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma" [Cancer Lett. 453 (2019… Co-author DOI 10.1016/j.canlet.2023.216059↗
  5. Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215864↗
  6. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-21-3230↗
  7. Identification of DDX31 as a Potential Oncogene of Invasive Metastasis and Proliferation in PDAC. Last author DOI 10.3389/fcell.2022.762372↗
  8. Serum insulin-like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma-associated malnutrition and muscle wasting. Co-author DOI 10.1002/jcsm.12692↗
  9. CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms. Co-author DOI 10.1016/j.canlet.2021.07.024↗
  10. DDX31: A Novel Functional Oncogene Promotes Migration and Proliferation of Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-520114/v1↗
  11. RETRACTED: HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2019.03.036↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 7 shared papers, 2019–2026 · strength 0.98
  2. Xiuchao Wang · 7 shared papers, 2019–2025 · strength 0.91
  3. Tiansuo Zhao · 6 shared papers, 2019–2025 · strength 0.78
  4. Yongjie Xie · 4 shared papers, 2021–2025 · strength 0.74
  5. Chongbiao Huang · 4 shared papers, 2021–2025 · strength 0.55
  6. Bo Ni · 3 shared papers, 2022–2025 · strength 0.55
  7. Shengyu Yang · 4 shared papers, 2021–2025 · strength 0.54
  8. Tianxing Zhou · 2 shared papers, 2025–2026 · strength 0.43
  9. Chuntao Gao · 2 shared papers, 2021–2026 · strength 0.37
  10. Song Gao · 3 shared papers, 2021–2022 · strength 0.36
  11. Yang Liu · 2 shared papers, 2021–2022 · strength 0.36
  12. Jinsheng Ding · 2 shared papers, 2021–2022 · strength 0.36
  13. Wenna Jiang · 1 shared paper, 2026 · strength 0.25
  14. Shangheng Shi · 1 shared paper, 2026 · strength 0.25
  15. Rui Liu · 1 shared paper, 2026 · strength 0.25
  16. Mingxiao Lang · 2 shared papers, 2019–2023 · strength 0.24
  17. Haotian Wang · 2 shared papers, 2019–2023 · strength 0.24
  18. Peng Jin · 1 shared paper, 2024 · strength 0.21
  19. Xiaona Wang · 1 shared paper, 2024 · strength 0.21
  20. Yuexiang Liang · 1 shared paper, 2024 · strength 0.21
  21. Bin Li · 1 shared paper, 2024 · strength 0.21
  22. Guannan Sheng · 1 shared paper, 2025 · strength 0.18
  23. Chunhua She · 1 shared paper, 2025 · strength 0.18
  24. Chao Xu · 1 shared paper, 2025 · strength 0.18
  25. Kaiyuan Wang · 1 shared paper, 2025 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.